Dossier - Page 1 - FirstWord Reports

Learn More The Future of Key Account Management in Pharma

Are you ready for fundamental disruption to key account management practice? While the Key Account Management (KAM) role will continue to prioritise the development of long-term, sustainable partnerships between...

Compare
Learn More Trends in Investment by Big Pharma

What direction are big pharma investments taking? The investment decisions made by the biggest players in core disease areas drive market trends—so it's crucial to understand where the big money is going and why...

Compare
Learn More Benchmarking Key Account Management Capabilities (2019)

What factors determine a Key Account Manager (KAM) team's size and structure? At what stage in a product's lifecycle are KAMs assigned and how many brands should a typical KAM support? What personal attributes and...

Compare
Learn More Biosimilars: The Importance of Real-World Evidence (2019)

Are you generating the right RWE to influence the right stakeholders? As the biosimilar sector continues to evolve and experience of their use deepens, what role should real-world evidence (RWE) now take in stakeholder...

Compare
Learn More Real-World Data Capabilities: Benchmarking Pharma Companies (2019)

Are you fully and efficiently exploiting real-world data across your business? The impact of real-world data (RWD) is growing but few companies are fully exploiting its potential across all clinical and commercial areas...

Compare
Learn More Financing High-Cost Therapies through Reinsurance

Could reinsurance allay health insurers' fear about high cell and gene therapy costs? With the prospect of many cell and gene therapies coming to market in the medium term, often with record breaking list prices and...

Compare
Learn More Orphan Drugs: The Importance of Real-World Evidence

Current expert thinking on how real-world evidence can refine orphan drug research, demonstrate stakeholder value and prove clinical effectiveness. Alarmed at the number of often highly-priced orphan drugs coming to...

Compare
Learn More Biosimilars: US Payer Insights (2019)

What do payers see as critical to unlocking the stalled US biosimilar sector? How do payers view the trends in the sluggish US biosimilar market and what initiatives do they want from pharma? Originator companies are...

Compare
Learn More Biosimilars: European Payer Insights (2019)

As the European biosimilars market surges, what do payers see as the next steps? The approval in 2018 of biosimilar versions of adalimumab (Abbvie's Humira) and trastuzumab (Roche's Herceptin) is a major boost to the...

Compare
Learn More Paying for Gene Therapy: Payer Insights

Payers caution pharma to think hard about price if they want support for their gene therapies The message from payers is stark: developers who present gene therapies with limited clinical data, eye wateringly high...

Compare
Learn More Orphan Drugs: Drivers of Market Growth (2019)

Orphan drugs: Building your profits or draining your resources? Substantial growth prospects in orphan drugs (more than double the overall pharma market) have enticed many pharma companies to enter the fray. But all...

Compare
Learn More Trends in KOL Experience Management

How well does your MSL KOL engagement activity compare to competitors? What tools are being used today to measure engagement with KOLs? How often are KOLs surveyed regarding satisfaction levels? Which metrics are...

Compare
Learn More Indication-level Pricing: Payer Insights

Can pharma persuade payers of the benefits of indication-level pricing? Advocates argue that indication-level pricing can bring new products on stream and results in wider patient access to new therapies. That's a good...

Compare
Learn More KAM Metrics: Measuring Success (2019)

Secure a successful future for your KAM teams by proving their true value KAM teams are still evolving but they're also concerned about their future. They need appropriate measures to demonstrate their true value...

Compare
Learn More MSL Teams: Field Force size and structure (2019)

What factors determine the optimum MSL field-based team size and structure? How many brands should MSL field-based teams represent and what constitutes an acceptable territory? What educational background and...

Compare
Learn More Real World Data and Evidence: Payer Insights

Payers have great expectations for real world data. Is pharma meeting them? It's sink or swim time. Advancements in drug data collection methodologies and deeper understanding of what can be achieved has finally opened...

Compare
Learn More The Impact of Drug Compounding on Pharma

Drug compounding meets unmet clinical needs, widens therapy choice and expands patient access to medicines. What are the lessons and opportunities for pharma? Drug compounding is a fast growing sector meeting the needs...

Compare
Learn More Review of Influence: The Institute for Clinical and Economic Review (ICER)

As the Institute for Clinical and Economic Review's (ICER) influence on payer behaviour and health policy grows, how should pharma respond? The ICER's novel and inclusive work on the value of drugs, using its own value...

Compare
Learn More The Future of CRISPR

Where will CRISPR deliver real value? Investors and pharma are enthusiastic about CRISPR gene editing technology: not only can it be used to develop new therapeutics, it has become a powerful tool in drug discovery,...

Compare
Learn More Trends in Pharma-Patient Engagement

Exactly how is Pharma organising and benefitting from its patient engagement strategy? How are patient engagement teams structured and resourced? When do teams engage with patients and what are the main...

Compare

Browse by